© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer
Veliparib Combination Induces Significant Improvement in PFS for BRCA-Like Advanced TNBC
June 03, 2020
“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."
Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355
June 03, 2020
Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Palbociclib Expected to Miss Its Mark in HR+, HER2– Breast Cancer
June 01, 2020
"We are disappointed [with] this outcome. Breast cancer is a leading cause of death around the world and delaying or preventing the development of metastatic disease is a significant unmet need. PALLAS is a large study with many subgroups and we are actively collaborating to determine if there are patients who may benefit from adjuvant treatment with the palbociclib combination."
Frontline Pembrolizumab Plus Chemo Shows Compelling PFS Improvement in PD-L1+ TNBC
May 29, 2020
"Pembrolizumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS as compared with chemotherapy alone for the first-line treatment of metastatic TNBC with a PD-L1 CPS of 10 or higher tumors."
Significant Delay in CNS Progression Achieved With Tucatinib Triplet in HER2+ Metastatic Breast Cancer
May 29, 2020
The addition of tucatinib to treatment with trastuzumab and capecitabine resulted in more than a 60% reduction in the risk of central nervous system progression or death in both patients with previously treated HER2-positive metastatic breast cancer who have active or stable brain metastases.
Alpelisib Generates Promising Responses in PI3KCA+ Breast Cancer After Progression on CDK Inhibitor
May 29, 2020
“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified."
Overall Survival Not Increased With Locoregional Therapy in Advanced Breast Cancer
May 28, 2020
"Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit."
Addressing the Mechanism of Action for the AKT Pathway in TNBC
May 26, 2020
Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Entinostat Combo Fails to Meet End Point in Phase 3 HR+/HER2– Breast Cancer Study
May 26, 2020
Entinostat plus exemestame did not improve overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.
Sacituzumab Govitecan Brings Long-Awaited Progress in the Treatment Landscape of mTNBC
May 25, 2020
In an interview with Targeted Oncology following the announcement of sacituzumab govitecan accelerated FDA approval, Hope Rugo, MD, discussed the published data from the phase 1/2 basket trial and the relevance of having sacituzumab govitecan available for the treatment of patients with metastatic triple negative breast cancer.